Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Gains from Investment Securities (2016 - 2025)

Medifast's Gains from Investment Securities history spans 16 years, with the latest figure at -$372000.0 for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 76.25% year-over-year to -$372000.0; the TTM value through Dec 2025 reached -$1.4 million, up 15.09%, while the annual FY2025 figure was -$1.4 million, 15.09% up from the prior year.
  • Gains from Investment Securities reached -$372000.0 in Q4 2025 per MED's latest filing, up from -$606000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $37.2 million in Q4 2022 to a low of -$41.3 million in Q4 2021.
  • Average Gains from Investment Securities over 5 years is $1.7 million, with a median of -$27536.5 recorded in 2021.
  • The largest YoY upside for Gains from Investment Securities was 3014.0% in 2025 against a maximum downside of 6853.06% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at -$41.3 million in 2021, then skyrocketed by 190.09% to $37.2 million in 2022, then decreased by 6.15% to $34.9 million in 2023, then tumbled by 104.48% to -$1.6 million in 2024, then skyrocketed by 76.25% to -$372000.0 in 2025.
  • Per Business Quant, the three most recent readings for MED's Gains from Investment Securities are -$372000.0 (Q4 2025), -$606000.0 (Q3 2025), and -$3.3 million (Q2 2025).